The primary genetic susceptibility factors in LCH involve gain-of-function mutations in the mitogen-activated protein kinase (MAPK) signaling pathway, notably the BRAF V600E and MAP2K1 mutations [12]. This evidence concerns the gene WNK2 and Langerhans cell histiocytosis.